BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 20087651)

  • 1. Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue.
    Weitzel LR; Byers T; Allen J; Finlayson C; Helmke SM; Hokanson JE; Hunsucker SW; Murphy JR; Newell K; Queensland KM; Singh M; Wischmeyer PE; Duncan MW; Elias A
    Breast Cancer Res Treat; 2010 Nov; 124(2):297-305. PubMed ID: 20087651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of serological proteomic methods to find biomarkers associated with breast cancer.
    Rui Z; Jian-Guo J; Yuan-Peng T; Hai P; Bing-Gen R
    Proteomics; 2003 Apr; 3(4):433-9. PubMed ID: 12687611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry.
    Rauser S; Marquardt C; Balluff B; Deininger SO; Albers C; Belau E; Hartmer R; Suckau D; Specht K; Ebert MP; Schmitt M; Aubele M; Höfler H; Walch A
    J Proteome Res; 2010 Apr; 9(4):1854-63. PubMed ID: 20170166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping.
    Ou K; Yu K; Kesuma D; Hooi M; Huang N; Chen W; Lee SY; Goh XP; Tan LK; Liu J; Soon SY; Bin Abdul Rashid S; Putti TC; Jikuya H; Ichikawa T; Nishimura O; Salto-Tellez M; Tan P
    J Proteome Res; 2008 Apr; 7(4):1518-28. PubMed ID: 18318472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis.
    Lai TC; Chou HC; Chen YW; Lee TR; Chan HT; Shen HH; Lee WT; Lin ST; Lu YC; Wu CL; Chan HL
    J Proteome Res; 2010 Mar; 9(3):1302-22. PubMed ID: 20052998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and validation of protein abundance differences between follicular thyroid neoplasms.
    Netea-Maier RT; Hunsucker SW; Hoevenaars BM; Helmke SM; Slootweg PJ; Hermus AR; Haugen BR; Duncan MW
    Cancer Res; 2008 Mar; 68(5):1572-80. PubMed ID: 18316623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of differentially expressed proteins of gamma-ray irradiated rat intestinal epithelial IEC-6 cells by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation-time of flight mass spectrometry.
    Bo Z; Yongping S; Fengchao W; Guoping A; Yongjiang W
    Proteomics; 2005 Feb; 5(2):426-32. PubMed ID: 15700242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
    Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
    Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium.
    Hudelist G; Singer CF; Pischinger KI; Kaserer K; Manavi M; Kubista E; Czerwenka KF
    Proteomics; 2006 Mar; 6(6):1989-2002. PubMed ID: 16470630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
    J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M; Bauer K; Pare M
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic profiling and interactome analysis of ER-positive/HER2/neu negative invasive ductal carcinoma of the breast: towards proteomics biomarkers.
    Korwar AM; Bhonsle HS; Ghole VS; Gawai KR; Koppikar CB; Kulkarni MJ
    OMICS; 2013 Jan; 17(1):27-40. PubMed ID: 23301641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic analysis of breast cancer tissues to identify biomarker candidates by gel-assisted digestion and label-free quantification methods using LC-MS/MS.
    Song MN; Moon PG; Lee JE; Na M; Kang W; Chae YS; Park JY; Park H; Baek MC
    Arch Pharm Res; 2012 Oct; 35(10):1839-47. PubMed ID: 23139137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Separation and identification of differentially expressed nuclear matrix proteins in breast carcinoma forming.
    He Q; Zhang SQ; Chu YL; Jia XL; Zhao LH; Wang XL
    Acta Oncol; 2010; 49(1):76-84. PubMed ID: 19878069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [2-DE profiling and differential analysis of human bronchial epithelial tissues in different stages of carcinogenesis].
    Wu XY; Li C; Xiao ZQ; Li JL; Feng XP; Yi H; Li MY; Chen ZC
    Ai Zheng; 2004 May; 23(5):522-30. PubMed ID: 15142447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Occult multicentric breast cancer].
    Vtorushin SV; Zab'ialova MV; Glushchenko SA; Perel'muter VM; Slonimskaia EM
    Vopr Onkol; 2009; 55(1):38-41. PubMed ID: 19435197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
    Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
    Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
    Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
    Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.